Nature’s Recent Scientific Reports Publication Describes How Apabetalone May Be a Powerful Agent Against HIV-1
December 12 2017 - 7:30AM
Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX)
announced today that a recent Nature Scientific Reports has
published a 12 page publication on BET (bromodomain and
extra-terminal) inhibitors; RVX-208 (apabetalone) and PFI-1 owned
by Resverlogix and Pfizer, respectively. The publication by
Lu et al, “BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from
latency”, (Scientific Reports 7, Article number: 16646,
https://www.nature.com/articles/s41598-017-16816-1) demonstrates
that both BET inhibitors can reactivate HIV-1 from latency.
Persistent latent reservoirs of HIV-1 in resting CD4+T cells are
the major obstacle in curing HIV-1 infection. Their conclusion
suggests that BET inhibitors, such as apabetalone (RVX-208), are a
group of leading compounds for potentially unmasking HIV-1 latency
to allow for viral eradication.
Mr. Donald McCaffrey, President and Chief
Executive Officer commented, “We are thrilled to learn that
additional third party researchers are once again confirming the
true potential of BET inhibitors such as apabetalone
(RVX-208). As HIV/AIDS has been a decades-long deadly
disease, we would like to extend an open invitation to any
interested parties, that have the resources, to expedite a new
program utilizing either apabetalone or one of our other follow-on
BET inhibitors to test this hypothesis and provide a novel
therapeutic for this terrible disease.”
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET
inhibitor selective for the second bromodomain (BD2) within the BET
protein called BRD4. This selective inhibition of apabetalone on
BD2 produces a specific set of biological effects with potentially
important benefits for patients with high-risk cardiovascular
disease (CVD), diabetes mellitus (DM), chronic kidney disease,
end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is the only selective BET bromodomain
inhibitor in human clinical trials. Apabetalone is currently being
studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL), and is
expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up
to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
(https://twitter.com/resverlogix_rvx)
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252
Or visit our website: www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Apr 2023 to Apr 2024